Oxadiazolyl-phenoxyalkylisoxazoles, compositions thereof and methods for their use as anti-picornaviral agents
Oxadiazolyl-phenoxyalkylisoxazoles and pharmaceutically acceptable salts thereof, compositions comprising oxadiazolyl-phenoxyalkylisoxazole compounds or pharmaceutically acceptable salts thereof and methods for using oxadiazolyl-phenoxyalkylisoxazole compounds or pharmaceutically acceptable salts thereof as anti-picornaviral agents are described herein. The methods include using pleconaril as a prodrug for conversion to anti-picornaviral compounds in vivo.
1. The compound of Formula I:
or a pharmaceutically acceptable salt thereof.
2. The compound of Formula II:
or a pharmaceutically acceptable salt thereof.
3. A composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
4. A composition comprising a compound according to claim 2 or a pharmaceutically acceptable salt thereof.
5. The composition according to claim 3 , further comprising a pharmaceutically acceptable vehicle.
6. The composition according to claim 4 , further comprising a pharmaceutically acceptable vehicle.
7. A method for treating a picornaviral infection in a patient, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.
8. A method for treating a picornaviral infection in a patient, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound according to claim 2 or a pharmaceutically acceptable salt thereof.
9. A method for inhibiting the growth of a picornaviral infection in a cell, said method comprising contacting a cell infected with a picornavirus with an inhibitory amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.
10. A method for inhibiting the growth of a picornaviral infection in a cell, said method comprising contacting a cell infected with a picornavirus with an inhibitory amount of the compound according to claim 2 or a pharmaceutically acceptable salt thereof.
11. A method according to claim 7 , wherein a precursor of said compound is administered in the form of a prodrug.
12. A method according to claim 8 , wherein a precursor of said compound is administered in the form of a prodrug.
13. A method according to claim 11 , wherein said prodrug is pleconaril.
14. A method according to claim 12 , wherein said prodrug is pleconaril.
15. A method of using pleconaril as a prodrug for treating picornaviral infections in a patient, said method comprising administering to said patient a therapeutically effective amount of pleconaril or a pharmaceutically acceptable salt thereof.
16. A method of using pleconaril as a prodrug for treating a patient infected with at least one picornavirus, said method comprising administering to said patient a therapeutically effective amount of pleconaril or a salt thereof whereby said administrating results in the in vivo production of the compound of Formula I:
or a salt thereof.
17. A method of using pleconaril as a prodrug for treating a patient infected with at least one picornavirus, said method comprising administering to said patient a therapeutically effective amount of pleconaril or a salt thereof whereby said administrating results in the in vivo production of the compound of Formula II:
or a salt thereof.